These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8727425)

  • 1. Prodrugs revisited: the "ad hoc" approach as a complement to ligand design.
    Testa B; Caldwell J
    Med Res Rev; 1996 May; 16(3):233-41. PubMed ID: 8727425
    [No Abstract]   [Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs.
    More SS; Vince R
    J Med Chem; 2008 Aug; 51(15):4581-8. PubMed ID: 18651729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prodrugs: goals, principles and outlook].
    Piotrovskiĭ LB; Dumpis MA
    Farmakol Toksikol; 1988; 51(6):17-25. PubMed ID: 3069492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugs.
    Våbenø J; Nielsen CU; Steffansen B; Lejon T; Sylte I; Jørgensen FS; Luthman K
    Bioorg Med Chem; 2005 Mar; 13(6):1977-88. PubMed ID: 15727852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigations.
    Våbenø J; Nielsen CU; Ingebrigtsen T; Lejon T; Steffansen B; Luthman K
    J Med Chem; 2004 Sep; 47(19):4755-65. PubMed ID: 15341490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships for dipeptide prodrugs of acyclovir: implications for prodrug design.
    Santos CR; Capela R; Pereira CS; Valente E; Gouveia L; Pannecouque C; De Clercq E; Moreira R; Gomes P
    Eur J Med Chem; 2009 Jun; 44(6):2339-46. PubMed ID: 18848738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
    Lin YS; Tungpradit R; Sinchaikul S; An FM; Liu DZ; Phutrakul S; Chen ST
    J Med Chem; 2008 Dec; 51(23):7428-41. PubMed ID: 19053781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from marketed and investigational prodrugs.
    Ettmayer P; Amidon GL; Clement B; Testa B
    J Med Chem; 2004 May; 47(10):2393-404. PubMed ID: 15115379
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules.
    Meier C; Balzarini J
    Antiviral Res; 2006 Sep; 71(2-3):282-92. PubMed ID: 16735066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and bioavailability evaluation of coumarin-based prodrug of meptazinol.
    Xie Q; Wang X; Wang X; Jiang Z; Qiu Z
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4953-6. PubMed ID: 16154745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
    Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
    J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy.
    Gosselin G; Girardet JL; Périgaud C; Benzaria S; Lefebvre I; Schlienger N; Pompon A; Imbach JL
    Acta Biochim Pol; 1996; 43(1):196-208. PubMed ID: 8790724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodrug strategies to overcome poor water solubility.
    Stella VJ; Nti-Addae KW
    Adv Drug Deliv Rev; 2007 Jul; 59(7):677-94. PubMed ID: 17628203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
    Boyer SH; Jiang H; Jacintho JD; Reddy MV; Li H; Li W; Godwin JL; Schulz WG; Cable EE; Hou J; Wu R; Fujitaki JM; Hecker SJ; Erion MD
    J Med Chem; 2008 Nov; 51(22):7075-93. PubMed ID: 18975928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
    Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
    Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ethylene glycol) anticancer drug delivery systems.
    Greenwald RB
    P R Health Sci J; 2002 Jun; 21(2):113-21. PubMed ID: 12166021
    [No Abstract]   [Full Text] [Related]  

  • 19. Pyrophosphate-bridged complexes with picomolar toxicity.
    Ikotun OF; Higbee EM; Ouellette W; Doyle RP
    J Inorg Biochem; 2009 Sep; 103(9):1254-64. PubMed ID: 19666193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactivation of carbamate-based 20(S)-camptothecin prodrugs.
    Pessah N; Reznik M; Shamis M; Yantiri F; Xin H; Bowdish K; Shomron N; Ast G; Shabat D
    Bioorg Med Chem; 2004 Apr; 12(8):1859-66. PubMed ID: 15051055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.